BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT03196206
- Locations
- 🇺🇸
Clinical Pharmacology of Miami LLC, Miami, Florida, United States
🇺🇸Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)
Phase 3
Withdrawn
- Conditions
- Giant Cell Arteritis
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03192969
- Locations
- 🇬🇧
Local Institution, London, United Kingdom
A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT03192943
- Locations
- 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan
A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36000
- Registration Number
- NCT03189069
A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 171
- Registration Number
- NCT03188081
- Locations
- 🇮🇹
Local Institution, Brescia, Italy
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Pancreatic CancerColorectal Cancer
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 332
- Registration Number
- NCT03184870
- Locations
- 🇺🇸
Local Institution - 0004, Hackensack, New Jersey, United States
🇺🇸Local Institution - 0033, Boston, Massachusetts, United States
🇺🇸Local Institution - 0027, Rochester, Minnesota, United States
Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults
Completed
- Conditions
- Hepatitis C
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 10
- Registration Number
- NCT03181074
- Locations
- 🇲🇽
Local Institution, Mexico, D.f., Distrito Federal, Mexico
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Completed
- Conditions
- Melanoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 68
- Registration Number
- NCT03165422
- Locations
- 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Completed
- Conditions
- Melanoma
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2017-10-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1828
- Registration Number
- NCT03165409
- Locations
- 🇺🇸
Bristol-Myers Squibb, Princeton, New Jersey, United States
Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico
Withdrawn
- Conditions
- Multiple Indications Cancer
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-05-22
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03161613
- Locations
- 🇲🇽
Local Institution, Mexico, Distrito Federal, Mexico
© Copyright 2025. All Rights Reserved by MedPath